SynAct Pharma: Another Directed Share Issue Solves Funding - Redeye

Redeye is positive about SynAct’s new directed issue and loan agreement with Hunter Capital, both of which have attractive conditions for the company. This funding will enable SynAct to start a new phase IIa study in polymyalgia rheumatica, which will have a positive impact on our base case.

Länk till analysen i sin helhet: https://www.redeye.se/research/1114329/synact-pharma-another-directed-share-issue-solves-funding?utm_source=finwire&utm_medium=RSS